Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Xianting Hu *Department of Otolaryngology, Head and Neck Surgery, Eye and ENT Hospital, Fudan University, Shanghai, China.ORCID 0009-0002-3904-939X
Zhi Liu *NOMIS Center for Immunology and Microbial Pathogenesis, Salk Institute for Biological Studies , La Jolla, CA, USA.ORCID 0009-0000-3299-0289
Yao Li *Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.ORCID 0009-0008-1296-3521
Yannan YouShanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.ORCID 0000-0002-8553-6394
Kaiye YueShanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.ORCID 0000-0002-1352-6912
Yuqiong LiangNOMIS Center for Immunology and Microbial Pathogenesis, Salk Institute for Biological Studies , La Jolla, CA, USA.ORCID 0009-0007-1242-7115
Chin-San LooNOMIS Center for Immunology and Microbial Pathogenesis, Salk Institute for Biological Studies , La Jolla, CA, USA.ORCID 0000-0001-7915-2995
Jingting YuRazavi Newman Integrative Genomics and Bioinformatics Core, Salk Institute for Biological Studies , La Jolla, CA, USA.ORCID 0009-0005-1182-3680
Dehui WangDepartment of Otolaryngology, Head and Neck Surgery, Eye and ENT Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-0346-3193
Huabin LiDepartment of Otolaryngology, Head and Neck Surgery, Eye and ENT Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-2477-2879
Ye ZhengNOMIS Center for Immunology and Microbial Pathogenesis, Salk Institute for Biological Studies , La Jolla, CA, USA.ORCID 0000-0001-5012-4309
Funding
Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8M
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapyP01AG073084 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PETER D. ADAMS, GERALD SHADEL · 2021 to 2026
$13.6M
San Diego Nathan Shock CenterP30AG068635 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SHADEL, GERALD · 2020 to 2024
$6.0M
Treg development and function controlled by cis-regulatory circuitsR01AI107027 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI ZHENG, YE · 2014 to 2022
$5.0M
High-throughput mapping of selectively vulnerable cell types and projections in aging and Alzheimer's DiseaseRF1AG064049 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI LEE, KUO-FEN, ZADOR, ANTHONY M · 2019 to 2019
$4.7M
The role of BAF related complexes in regulatory T cell development and functionR01AI151123 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI HARGREAVES, DIANA CLARE, ZHENG, YE · 2020 to 2024
$4.0M
Spectral Configured Bigfoot Sorter for Salk Institute Flow Cytometry CoreS10OD034268 · OD · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI O'CONNOR, CAROLYN PEY-MIN · 2023 to 2023
$724k
BD FACSAria Fusion for Flow Cytometry Core FacilityS10OD023689 · OD · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI ZHENG, YE · 2018 to 2018
$530k
Define the role of REV-ERB in colonic RORgt+ regulatory T cellsR21AI178938 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI ZHENG, YE · 2023 to 2024
$523k
The role of PPARd-controlled CIITA/MHCII expression in Treg's function in tumor immunityR21AI188938 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Ye Zheng · 2025 to 2026
$514k
Crohn's and Colitis FoundationNational Natural Science Foundation of China 32370937National Natural Science Foundation of China 32571040National Natural Science Foundation of China 82301277NCI NIH HHS P30 CA014195NCI NIH HHS P30-CA014195NIAID NIH HHS R01 AI107027NIAID NIH HHS R01 AI151123NIAID NIH HHS R21 AI178938NIAID NIH HHS R21 AI188938NIA NIH HHS P01 AG073084NIA NIH HHS P01-AG073084NIA NIH HHS P30 AG068635NIA NIH HHS P30-AG068635NIA NIH HHS RF1 AG064049NIA NIH HHS RF1-AG064049NIH HHS R01-AI107027NIH HHS R01-AI1511123NIH HHS R21-AI178938NIH HHS R21-AI188938NIH HHS S10 OD023689NIH HHS S10-OD023689NIH HHS S10 OD034268NIH HHS S10-OD034268NOMIS FoundationNoncommunicable Chronic Diseases-National Science and Technology 2023ZD05032040Salk Institute P30-CA014195Shanghai Immune Therapy InstituteSol Goldman Charitable Trust
6 · The paper itself
Abstract
Foxp3+ regulatory T (Treg) cells co-expressing RORγt adopt specialized functions to restrain intestinal inflammation. However, despite extensive characterization, the factors governing RORγt+Foxp3+ Treg specialization remain unclear. Here, we report that transcriptional repressor REV-ERB is critical for the differentiation and function of colonic RORγt+Foxp3+ Treg cells. REV-ERB deficiency exacerbates both TNBS- and oxazolone-induced intestinal inflammation. Mechanistically, REV-ERB promotes RORγt expression through suppressing the expression of transcriptional repressor Bhlhe40, which in turn inhibits c-Maf, a key factor promoting colonic RORγt+Foxp3+ Treg differentiation and function. Moreover, this Bhlhe40-c-Maf axis downstream of REV-ERB also regulates the expression of core colonic Treg signature genes including IL-10 and CTLA-4, while REV-ERB additionally safeguards RORγt+Foxp3+ Treg functional stability by directly suppressing proinflammatory cytokine IL-17A production. Collectively, the present study identifies that REV-ERB along with the downstream Bhlhe40-c-Maf axis jointly controls the RORγt+Foxp3+ Treg differentiation and suppressive function, suggesting that modulating their activities may strengthen RORγt+Foxp3+ Treg function to ameliorate inflammatory bowel diseases.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
REV-ERB regulates RORγt+ regulatory T cell specification and function through the Bhlhe40-c-Maf axis. · full record | OpenQuestion